06/11/2025
Here are some international studies regarding Eltrombopag in dengue-induced thrombocytopenia ¹ ² ³:
- *Phase II Randomized Controlled Clinical Trial*: A study published in EClinicalMedicine investigated the efficacy and safety of Eltrombopag in correcting thrombocytopenia in moderate to severe dengue patients. The trial showed that Eltrombopag was efficacious in increasing platelet counts and reducing bleeding manifestations in dengue patients.
- *Systematic Review*: A systematic review published in Research Journal of Pharmacy and Technology examined the available literature on the use of Eltrombopag Olamine for the treatment of dengue fever. The review highlighted Eltrombopag Olamine's potential in managing dengue fever by increasing platelet counts and reducing fluid leakage.
- *Phase III Randomized Placebo Controlled Clinical Trial*: A study registered on ClinicalTrials.gov (SLCTR/2022/023) is investigating the efficacy and safety of Eltrombopag in correcting thrombocytopenia and preventing fluid leakage in moderate to severe dengue patients.
- *Study on Papaya Leaf Extract*: A study published in the Sri Lanka Clinical Trials Registry (SLCTR/2017/034) explored the effects of papaya leaf extract on plasma leakage and platelet count in dengue fever patients.
These studies demonstrate the potential of Eltrombopag in treating dengue-induced thrombocytopenia. However, further research is needed to establish its efficacy and safety in different patient populations.
Some key findings include:
- *Efficacy*: Eltrombopag was shown to be efficacious in increasing platelet counts and reducing bleeding manifestations in dengue patients.
- *Safety*: The studies suggest that Eltrombopag is safe to administer in dengue patients, with a lower dose (25 mg/day) appearing to be safer than a higher dose (50 mg/day).
- *Mechanism*: Eltrombopag works by stimulating megakaryopoiesis in the bone marrow, leading to increased platelet production.